Last reviewed · How we verify
Hermann Eye Center — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Alphagan P | Alphagan P | marketed | ||||
| Lidocaine 2% Jelly | Lidocaine 2% Jelly | marketed | Local anesthetic | Voltage-gated sodium channels | Anesthesia/Ophthalmology |
Therapeutic area mix
- Anesthesia/Ophthalmology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams Maternity Hospital · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Aligarh Muslim University · 1 shared drug class
- Atlantic Health System · 1 shared drug class
- Aultman Health Foundation · 1 shared drug class
- B.P. Koirala Institute of Health Sciences · 1 shared drug class
- Bagcilar Training and Research Hospital · 1 shared drug class
- Abant Izzet Baysal University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Hermann Eye Center:
- Hermann Eye Center pipeline updates — RSS
- Hermann Eye Center pipeline updates — Atom
- Hermann Eye Center pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Hermann Eye Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hermann-eye-center. Accessed 2026-06-10.